Abrogation of Src homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo

Journal of Immunology

Volumn 189, Issue 4, 2012, Pages 1812-1825

  Stromnes, Ingunn M ^a   Fowler, Carla ^a   Casamina, Chanel C ^a   Georgopolos, Christina M ^a   McAfee, Megan S ^b   Schmitt, Thomas M ^c   Tan, Xiaoxia ^a   Kim, Tae Don ^d   Choi, Inpyo ^d   Blattman, Joseph N ^c   Greenberg, Philip D ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EOMESODERMIN; INTERLEUKIN 2; PROTEIN TYROSINE PHOSPHATASE SHP 1; RETROVIRUS VECTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; EFFECTOR CELL; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LYMPHOCYTE PROLIFERATION; MEMORY CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL;

ANIMALS; ANTIGENS, NEOPLASM; DISEASE MODELS, ANIMAL; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; MICE; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 84864797384     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200552     Document Type: Article

References (86)

1. Yee, C., J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg. 2000. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192: 1637-1644.
2. Dudley, M. E., and S. A. Rosenberg. 2003. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 3: 666-675. (Pubitemid 37328821)
3. Kalos, M., B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp, A. Bagg, and C. H. June. 2011. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3: 95ra73.
4. Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8: 299-308. (Pubitemid 351430867)
5. Schmitt, T. M., G. B. Ragnarsson, and P. D. Greenberg. 2009. T cell receptor gene therapy for cancer. Hum. Gene Ther. 20: 1240-1248.
6. Kammula, U. S., D. E. White, and S. A. Rosenberg. 1998. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83: 797-805. (Pubitemid 28387707)
7. Gattinoni, L., S. E. Finkelstein, C. A. Klebanoff, P. A. Antony, D. C. Palmer, P. J. Spiess, L. N. Hwang, Z. Yu, C. Wrzesinski, D. M. Heimann, et al. 2005. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202: 907-912. (Pubitemid 41396891)
8. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357. (Pubitemid 46218728)
9. Klebanoff, C. A., S. E. Finkelstein, D. R. Surman, M. K. Lichtman, L. Gattinoni, M. R. Theoret, N. Grewal, P. J. Spiess, P. A. Antony, D. C. Palmer, et al. 2004. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. USA 101: 1969-1974. (Pubitemid 38228999)
10. + T cells for use in adoptive immunotherapy of established tumors. Nat. Med. 12: 335-341.
11. Fewkes, N. M., and C. L. Mackall. 2010. Novel γ-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J. 16: 392-398.
12. Ho, W. Y., J. N. Blattman, M. L. Dossett, C. Yee, and P. D. Greenberg. 2003. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3: 431-437. (Pubitemid 38340289)
13. Blattman, J. N., and P. D. Greenberg. 2004. Cancer immunotherapy: a treatment for the masses. Science 305: 200-205. (Pubitemid 38886725)
14. Stromnes, I. M., J. N. Blattman, X. Tan, S. Jeevanjee, H. Gu, and P. D. Greenberg. 2010. Abrogating Cbl-b in effector CD8+ T cells improves the efficacy of adoptive therapy of leukemia in mice. J. Clin. Invest. 120: 3722-3734.
15. Lorenz, U. 2009. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol. Rev. 228: 342-359.
16. Johnson, K. G., F. G. LeRoy, L. K. Borysiewicz, and R. J. Matthews. 1999. TCR signaling thresholds regulating T cell development and activation are dependent upon SHP-1. J. Immunol. 162: 3802-3813. (Pubitemid 29314757)
17. Dittel, B. N., I. Stefanova, R. N. Germain, and C. A. Janeway, Jr. 1999. Cross-antagonism of a T cell clone expressing two distinct T cell receptors. Immunity 11: 289-298. (Pubitemid 29463237)
18. Stefanová, I., B. Hemmer, M. Vergelli, R. Martin, W. E. Biddison, and R. N. Germain. 2003. TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat. Immunol. 4: 248-254. (Pubitemid 36322134)
19. Kilgore, N. E., J. D. Carter, U. Lorenz, and B. D. Evavold. 2003. Cutting edge: dependence of TCR antagonism on Src homology 2 domain-containing protein tyrosine phosphatase activity. J. Immunol. 170: 4891-4895. (Pubitemid 36554717)
20. + T cell responses to a viral escape mutant epitope: active suppression via altered SHP-1 activity. J. Immunol. 182: 1829-1835.
21. Lorenz, U., K. S. Ravichandran, S. J. Burakoff, and B. G. Neel. 1996. Lack of SHPTP1 results in src-family kinase hyperactivation and thymocyte hyperresponsiveness. Proc. Natl. Acad. Sci. USA 93: 9624-9629. (Pubitemid 26296658)
22. Chiang, G. G., and B. M. Sefton. 2001. Specific dephosphorylation of the Lck tyrosine protein kinase at Tyr-394 by the SHP-1 protein-tyrosine phosphatase. J. Biol. Chem. 276: 23173-23178.
23. Plas, D. R., R. Johnson, J. T. Pingel, R. J. Matthews, M. Dalton, G. Roy, A. C. Chan, and M. L. Thomas. 1996. Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Science 272: 1173-1176. (Pubitemid 26169472)
24. Brockdorff, J., S. Williams, C. Couture, and T. Mustelin. 1999. Dephosphorylation of ZAP-70 and inhibition of T cell activation by activated SHP1. Eur. J. Immunol. 29: 2539-2550. (Pubitemid 29378125)
25. Stebbins, C. C., C. Watzl, D. D. Billadeau, P. J. Leibson, D. N. Burshtyn, and E. O. Long. 2003. Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity. Mol. Cell. Biol. 23: 6291-6299. (Pubitemid 37013105)
26. Cuevas, B., Y. Lu, S. Watt, R. Kumar, J. Zhang, K. A. Siminovitch, and G. B. Mills. 1999. SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity. J. Biol. Chem. 274: 27583-27589.
27. Sozio, M. S., M. A. Mathis, J. A. Young, S. Wälchli, L. A. Pitcher, P. C. Wrage, B. Bartók, A. Campbell, J. D. Watts, R. Aebersold, et al. 2004. PTPH1 is a predominant protein-tyrosine phosphatase capable of interacting with and dephosphorylating the T cell receptor z subunit. J. Biol. Chem. 279: 7760-7769. (Pubitemid 38294659)
28. + T cell-APC conjugate formation and is associated with enhanced in vivo CTL function. J. Immunol. 178: 330-337.
29. + tumor-infiltrating T cells. Cancer Res. 67: 11447-11454.
30. Fowler, C. C., L. I. Pao, J. N. Blattman, and P. D. Greenberg. 2010. SHP-1 in T cells limits the production of CD8 effector cells without impacting the formation of long-lived central memory cells. J. Immunol. 185: 3256-3267.
31. Tsui, H. W., K. A. Siminovitch, L. de Souza, and F. W. Tsui. 1993. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat. Genet. 4: 124-129.
32. Shultz, L. D., T. V. Rajan, and D. L. Greiner. 1997. Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotechnol. 15: 302-307. (Pubitemid 27330625)
33. Khaled, A. R., E. J. Butfiloski, E. S. Sobel, and J. Schiffenbauer. 1998. Functional consequences of the SHP-1 defect in motheaten viable mice: role of NF-κB. Cell. Immunol. 185: 49-58. (Pubitemid 28272674)
34. Carter, J. D., B. G. Neel, and U. Lorenz. 1999. The tyrosine phosphatase SHP-1 influences thymocyte selection by setting TCR signaling thresholds. Int. Immunol. 11: 1999-2014.
35. + T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J. Exp. Med. 195: 1407-1418.
36. + T cells or CTL immunotherapy of tumors expressing the antigen. J. Immunol. 166: 2863-2870.
37. Pao, L. I., K. P. Lam, J. M. Henderson, J. L. Kutok, M. Alimzhanov, L. Nitschke, M. L. Thomas, B. G. Neel, and K. Rajewsky. 2007. B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 27: 35-48. (Pubitemid 47089020)
38. Srinivas, S., T. Watanabe, C. S. Lin, C. M. William, Y. Tanabe, T. M. Jessell, and F. Costantini. 2001. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 1: 4.
39. Zhang, D. J., Q. Wang, J. Wei, G. Baimukanova, F. Buchholz, A. F. Stewart, X. Mao, and N. Killeen. 2005. Selective expression of the Cre recombinase in late-stage thymocytes using the distal promoter of the Lck gene. J. Immunol. 174: 6725-6731. (Pubitemid 40705634)
40. Chen, D., H. Iijima, T. Nagaishi, A. Nakajima, S. Russell, R. Raychowdhury, V. Morales, C. E. Rudd, N. Utku, and R. S. Blumberg. 2004. Carcinoembryonic antigen-related cellular adhesion molecule 1 isoforms alternatively inhibit and costimulate human T cell function. J. Immunol. 172: 3535-3543. (Pubitemid 38337934)
41. Wang, N., Z. Li, R. Ding, G. D. Frank, T. Senbonmatsu, E. J. Landon, T. Inagami, and Z. J. Zhao. 2006. Antagonism or synergism: role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling. J. Biol. Chem. 281: 21878-21883. (Pubitemid 44181891)
42. Nagaishi, T., L. Pao, S. H. Lin, H. Iijima, A. Kaser, S. W. Qiao, Z. Chen, J. Glickman, S. M. Najjar, A. Nakajima, et al. 2006. SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity 25: 769-781. (Pubitemid 46107284)
43. + T cells become nonresponsive (anergic) following activation in the presence of costimulation. J. Immunol. 163: 102-110.
44. Blattman, J. N., R. Antia, D. J. Sourdive, X. Wang, S. M. Kaech, K. Murali-Krishna, J. D. Altman, and R. Ahmed. 2002. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J. Exp. Med. 195: 657-664. (Pubitemid 34461511)
45. Yee, C. 2010. Adoptive therapy using antigen-specific T-cell clones. Cancer J. 16: 367-373.
46. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129. (Pubitemid 44547756)
47. Miethke, T., R. Vabulas, R. Bittlingmaier, K. Heeg, and H. Wagner. 1996. Mechanisms of peripheral T cell deletion: anergized T cells are Fas resistant but undergo proliferation-associated apoptosis. Eur. J. Immunol. 26: 1459-1467. (Pubitemid 26229989)
48. + T cell function by the transcription factor Eomesodermin. Science 302: 1041-1043.
49. Cruz-Guilloty, F., M. E. Pipkin, I. M. Djuretic, D. Levanon, J. Lotem, M. G. Lichtenheld, Y. Groner, and A. Rao. 2009. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J. Exp. Med. 206: 51-59.
50. + T cell fates via the graded expression of T-bet transcription factor. Immunity 27: 281-295.
51. Qui, H. Z., A. T. Hagymasi, S. Bandyopadhyay, M. C. St Rose, R. Ramanarasimhaiah, A. Ménoret, R. S. Mittler, S. M. Gordon, S. L. Reiner, A. T. Vella, and A. J. Adler. 2011. CD134 plus CD137 dual costimulation induces eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J. Immunol. 187: 3555-3564.
52. Cheever, M. A., D. B. Thompson, J. P. Klarnet, and P. D. Greenberg. 1986. Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J. Exp. Med. 163: 1100-1112. (Pubitemid 16000411)
53. + T cells expressing a known endogenous TCR. Mol. Ther. 17: 742-749.
54. Greenberg, P. D., and M. A. Cheever. 1984. Effector mechanisms operative in adoptive therapy of tumor-bearing animals: implications for the use of interleukin-2. J. Biol. Response Mod. 3: 455-461. (Pubitemid 14013605)
55. +T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173.
56. Berger, C., C. J. Turtle, M. C. Jensen, and S. R. Riddell. 2009. Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr. Opin. Immunol. 21: 224-232.
57. + T cells to a transgenic autoantigen expressed in the liver does not require cross-presentation. J. Immunol. 178: 6849-6860.
58. Surh, C. D., and J. Sprent. 2008. Homeostasis of naive and memory T cells. Immunity 29: 848-862.
59. Grabstein, K. H., T. J. Waldschmidt, F. D. Finkelman, B. W. Hess, A. R. Alpert, N. E. Boiani, A. E. Namen, and P. J. Morrissey. 1993. Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody. J. Exp. Med. 178: 257-264. (Pubitemid 23173261)
60. Restifo, N. P., F. Esquivel, Y. Kawakami, J. W. Yewdell, J. J. Mulé, S. A. Rosenberg, and J. R. Bennink. 1993. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177: 265-272. (Pubitemid 23117076)
61. Garcia-Lora, A., I. Algarra, and F. Garrido. 2003. MHC class I antigens, immune surveillance, and tumor immune escape. J. Cell. Physiol. 195: 346-355. (Pubitemid 36529863)
62. Amos, S. M., C. P. Duong, J. A. Westwood, D. S. Ritchie, R. P. Junghans, P. K. Darcy, and M. H. Kershaw. 2011. Autoimmunity associated with immunotherapy of cancer. Blood 118: 499-509.
63. Morgan, R. A., J. C. Yang, M. Kitano, M. E. Dudley, C. M. Laurencot, and S. A. Rosenberg. 2010. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18: 843-851.
64. + T cell tolerance to self-proteins is regulated proximally at the T cell receptor. Immunity 28: 662-674.
65. Guidotti, L. G., T. Ishikawa, M. V. Hobbs, B. Matzke, R. Schreiber, and F. V. Chisari. 1996. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4: 25-36. (Pubitemid 26054933)
66. Kafrouni, M. I., G. R. Brown, and D. L. Thiele. 2001. Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms. J. Immunol. 167: 1566-1574. (Pubitemid 32703157)
67. Crispe, I. N. 2009. The liver as a lymphoid organ. Annu. Rev. Immunol. 27: 147-163.
68. Peters, M. G. 2002. Animal models of autoimmune liver disease. Immunol. Cell Biol. 80: 113-116. (Pubitemid 34415541)
69. Wiede, F., B. J. Shields, S. H. Chew, K. Kyparissoudis, C. van Vliet, S. Galic, M. L. Tremblay, S. M. Russell, D. I. Godfrey, and T. Tiganis. 2011. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. J. Clin. Invest. 121: 4758-4774.
70. Murthy, A., Y. W. Shao, V. Defamie, C. Wedeles, D. Smookler, and R. Khokha. 2012. Stromal TIMP3 regulates liver lymphocyte populations and provides protection against Th1 T cell-driven autoimmune hepatitis. J. Immunol. 188: 2876-2883.
71. Holdener, M., E. Hintermann, M. Bayer, A. Rhode, E. Rodrigo, G. Hintereder, E. F. Johnson, F. J. Gonzalez, J. Pfeilschifter, M. P. Manns, et al. 2008. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J. Exp. Med. 205: 1409-1422. (Pubitemid 351831496)
72. + T cells exhibit multifunctional effector and helper responses, in vitro. Clin. Immunol. 136: 338-347.
73. Kamata, T., M. Yamashita, M. Kimura, K. Murata, M. Inami, C. Shimizu, K. Sugaya, C. R. Wang, M. Taniguchi, and T. Nakayama. 2003. Src homology 2 domain-containing tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation. J. Clin. Invest. 111: 109-119. (Pubitemid 36134854)
74. Mauldin, I. S., K. S. Tung, and U. M. Lorenz. 2012. The tyrosine phosphatase SHP-1 dampens murine Th17 development. Blood 119: 4419-4429.
75. + T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117: 808-814.
76. Arens, R., and S. P. Schoenberger. 2010. Plasticity in programming of effector and memory CD8 T-cell formation. Immunol. Rev. 235: 190-205.
77. + T cells: foot soldiers of the immune system. Immunity 35: 161-168.
78. + T cell responses in lymph nodes. Immunity 33: 412-423.
79. Chen, Z., L. Chen, S. W. Qiao, T. Nagaishi, and R. S. Blumberg. 2008. Carcinoembryonic antigen-related cell adhesion molecule 1 inhibits proximal TCR signaling by targeting ZAP-70. J. Immunol. 180: 6085-6093.
80. Murphy, T. L., and K. M. Murphy. 2010. Slow down and survive: enigmatic immunoregulation by BTLA and HVEM. Annu. Rev. Immunol. 28: 389-411.
81. Chemnitz, J. M., R. V. Parry, K. E. Nichols, C. H. June, and J. L. Riley. 2004. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173: 945-954. (Pubitemid 38924267)
82. Perez-Villar, J. J., G. S. Whitney, M. A. Bowen, D. H. Hewgill, A. A. Aruffo, and S. B. Kanner. 1999. CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol. Cell. Biol. 19: 2903-2912. (Pubitemid 29144535)
83. Taylor, A., M. Akdis, A. Joss, T. Akkoç, R. Wenig, M. Colonna, I. Daigle, E. Flory, K. Blaser, and C. A. Akdis. 2007. IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1. J. Allergy Clin. Immunol. 120: 76-83. (Pubitemid 46990499)
84. Taylor, A., J. Verhagen, T. Akkoç, R. Wenig, E. Flory, K. Blaser, M. Akdis, and C. A. Akdis. 2009. IL-10 suppresses CD2-mediated T cell activation via SHP-1. Mol. Immunol. 46: 622-629.
85. + T cells through the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-1. J. Immunol. 175: 5666-5674.
86. + T cells. Immunity 31: 131-144.